AngioLab (XKRX:251280) ROCE % : -72.07% (As of Dec. 2023)

View and export this data going back to 2016. Start your Free Trial

What is AngioLab ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. AngioLab's annualized ROCE % for the quarter that ended in Dec. 2023 was -72.07%.

AngioLab ROCE % Historical Data

The historical data trend for AngioLab's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AngioLab ROCE % Chart

AngioLab Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-45.21

-37.68

-72.07

AngioLab Semi-Annual Data
	Dec17	Dec18	Dec19	Dec20	Dec21	Dec22	Dec23
ROCE %	Get a 7-Day Free Trial			-	-	-45.21	-37.68	-72.07

AngioLab ROCE % Calculation

AngioLab's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-2316.906	/	( ( (4997.03 - 643.877)	+	(3918.531 - 1842.377) )	/ 2 )
	=	-2316.906	/	( (4353.153	+	2076.154)	/ 2 )
	=	-2316.906	/	3214.6535
	=	-72.07 %

AngioLab's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Dec. 2022 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Dec. 2022 )		(Q: Dec. 2023 )
	=	-2316.906	/	( ( (4997.03 - 643.877)	+	(3918.531 - 1842.377) )	/ 2 )
	=	-2316.906	/	( ( 4353.153	+	2076.154 )	/ 2 )
	=	-2316.906	/	3214.6535
	=	-72.07 %

(1) Note: The EBIT data used here is one times the annual (Dec. 2023) EBIT data.

AngioLab (XKRX:251280) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

AngioLab ROCE % Related Terms

Thank you for viewing the detailed overview of AngioLab's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

AngioLab (XKRX:251280) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AngioLab Inc (XKRX:251280) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

65 Techno 3ro, Suite 159, Hanshin S Mecca, Yuseong-gu, Doejeon, CHN

Website

http://www.angiolab.co.kr

AngioLab Inc is a biotechnology company. It develops products based on angiogenesis inhibitors. It discovers, develops, and markets anti-angiogenic candidates to inhibit the abnormal growth of new blood vessel.

AngioLab (XKRX:251280) Headlines

No Headlines